retatrutide expected approval date 🎙️ NEW EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Tirzepatide vs. Retatrutide: Key Differences

GLP1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: Systematic review and metaanalysis

Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, et al

The company has also partnered with third-party laboratories to study and validate the myGLP systems results

Echo Res Pract 4(1):R15-r20 Huggins GS, Kinnamon DD, Haas GJ, Jordan E, Hofmeyer M, Kransdorf E, Ewald GA, Morris AA, Owens A, Lowes B, Stoller D, Tang WHW, Garg S, Trachtenberg BH, Shah P, Pamboukian SV, Sweitzer NK, Wheeler MT, Wilcox JE, Katz S, Pan S, Jimenez J, Aaronson KD, Fishbein DP, Smart F, Wang J, Gottlieb SS, Judge DP, Moore CK, Mead JO, Ni H, Burke W, Hershberger RE (2022) Prevalence and cumulative risk of familial idiopathic dilated cardiomyopathy

Cyclosporine should only be used during pregnancy if the benefits outweigh the potential risks

EICHNER, M